HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.77M | 56.62M | 56.94M | 58.89M | 60.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.77M | 56.62M | 56.94M | 58.89M | 60.79M |
| Cost of Revenue | 15.46M | 14.66M | 14.36M | 14.23M | 13.72M |
| Gross Profit | 41.31M | 41.96M | 42.59M | 44.67M | 47.07M |
| SG&A Expenses | 25.57M | 26.93M | 26.75M | 27.30M | 28.17M |
| Depreciation & Amortization | 22.16M | 22.72M | 24.33M | 27.03M | 29.54M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.18M | 64.31M | 65.43M | 68.55M | 71.42M |
| Operating Income | -6.41M | -7.69M | -8.49M | -9.66M | -10.63M |
| Income Before Tax | -13.91M | -15.58M | -17.97M | -20.39M | -28.11M |
| Income Tax Expenses | 4.08M | 4.07M | 4.06M | 3.70M | -261.00K |
| Earnings from Continuing Operations | -17.99 | -19.66 | -22.03 | -24.09 | -27.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.99M | -19.66M | -22.03M | -24.09M | -27.85M |
| EBIT | -6.41M | -7.69M | -8.49M | -9.66M | -10.63M |
| EBITDA | 15.70M | 14.99M | 15.77M | 17.30M | 18.84M |
| EPS Basic | -0.67 | -0.72 | -0.69 | -0.75 | -0.87 |
| Normalized Basic EPS | -0.40 | -0.43 | -0.41 | -0.42 | -0.43 |
| EPS Diluted | -0.68 | -0.73 | -0.70 | -0.76 | -0.87 |
| Normalized Diluted EPS | -0.40 | -0.43 | -0.41 | -0.42 | -0.43 |
| Average Basic Shares Outstanding | 125.65M | 125.80M | 127.34M | 127.79M | 128.31M |
| Average Diluted Shares Outstanding | 125.65M | 125.80M | 127.34M | 127.79M | 128.31M |
| Dividend Per Share | -- | -- | 0.00 | 0.00 | 0.04 |
| Payout Ratio | -- | -- | 0.00% | 0.00% | -4.37% |